<DOC>
	<DOCNO>NCT02856620</DOCNO>
	<brief_summary>The role cardiac mechanic , circulate biomarkers frailty predict outcome patient aortic stenosis aortic valve replacement ( SCRABLES -The 2-Parts Study ) Part I : Observational study characterize phenotype , structural alteration biomarkers profile broad spectrum patient aortic stenosis heart failure preserve ejection fraction ( HFpEF ) . Part II : Prospective cohort study characterize patient ' phenotype , cardiac structural alteration , circulate biomarkers frailty order optimize risk stratification patient selection aortic valve intervention .</brief_summary>
	<brief_title>The Role Cardiac Mechanics , Biomarkers Frailty Aortic Stenosis</brief_title>
	<detailed_description>Part I : This part observational exploratory analysis collate available data Treatment preserve cardiac function heart failure aldosterone antagonist trial ( TOPCAT ) cohort regard potential role clinical phenotype , structural alteration biomarkers profile help determine symptom severity AS HFpEF , offer insight patient AS may suffer HFpEF aortic valve replacement ( AVR ) . Part II : This part prospective cohort study create AS functional capacity score include phenotypic classification , structural alteration use novel echocardiographic parameter cardiac mechanic , biomarkers profile frailty evaluation order accurately predict functional capacity ( Segment A ) aortic valve intervention ( Segment B ) compare healthy control group ( Segment C ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Part I Patients part TOPCAT cohort Americas fulfil inclusion criterion Part IIGroup 3 ( see ) and/or patient enrol Part II study Part II Segment A B Age ≥ 18 year old AS classified accord aortic valve area measure Doppler echocardiography Group 1 : Moderate AS ( 1.01.5cm2 ) Group 2 : Severe AS ( 1cm2 ) Group 3 : HF preserve leave ventricular ejection fraction ( LVEF ≥45 % ) without significant AS Part II Segment C ( Control Group ) Age ≥ 18 year old Healthy subject take account exclusion parameter time screen Able sign consent form Part I II Segment A B Prior AVR either surgery transaortic valve implantation ; Severe mitral valve disease aortic regurgitation ; LVEF &lt; 45 % Myocardial infarction within previous 3 month ; Angina limit 6MWTD thought result severe coronary artery disease ; Cerebrovascular transient ischemic attack stroke within previous 6 month ; Known active infection cancer ; renal insufficiency ( glomerular filtration rate &lt; 30 mL/min/1.73m2 ) endstage renal disease ; Significant anemia ( haemoglobin &lt; 90 g/L ) thrombocytopenia ( platelet count &lt; 50 ) , history bleed diathesis coagulopathy ; Life expectancy &lt; 12 month due noncardiac comorbid condition ; Chronic obstructive pulmonary disease Global initiative chronic obstructive lung disease ( GOLD ) stag 34 ; musculoskeletal disease limit ability perform 6MWTD . Part II Segment C ( Control Group ) History cardiovascular disease Risk factor associate cardiovascular ( treated diabetes , hypertension , body mass index &gt; 30kg/m2 ) Pregnancy breastfeed All cause Segment A B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cardiac mechanic</keyword>
	<keyword>circulate biomarkers</keyword>
	<keyword>frailty</keyword>
</DOC>